REmission in Membranous Nephropathy International Trial (REMIT)
- Status
- WITHDRAWN
- Phase
- PHASE3
Clinical Trials Related to Obinutuzumab
Related studies linked through entity extraction aliases.
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- Status
- RECRUITING
- Phase
- PHASE2
Obinutuzumab in Chinese Real-world Patients With iNHL
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
- Status
- RECRUITING
- Phase
- NA
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
- Status
- RECRUITING
- Phase
- N/A
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
- Status
- WITHDRAWN
- Phase
- PHASE1
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
- Status
- RECRUITING
- Phase
- PHASE2
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
- Status
- RECRUITING
- Phase
- PHASE2
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
- Status
- RECRUITING
- Phase
- PHASE2
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- UNKNOWN
- Phase
- NA